

51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Datinvest International Ltd. (the “Issuer”)
Suite 918 - 1030 West Georgia Street
Vancouver, BC, V6E 2Y3

Item 2 Date of Material Change

March 19, 2019

Item 3 News Release

The news release was disseminated through Stockwatch and SEDAR

Item 4 Summary of Material Change

Datinvest International Ltd. announces that the definitive amalgamation agreement entered into with Exxel Pharma Inc. has been terminated effective immediately. In connection with the proposed acquisition of Exxel Pharma, no funds were advanced to Exxel Pharma or any of its related parties and the Company did not assume any contingent liabilities or guarantees.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

Datinvest International Ltd. announces that the definitive amalgamation agreement entered into with Exxel Pharma Inc. has been terminated effective immediately. In connection with the proposed acquisition of Exxel Pharma, no funds were advanced to Exxel Pharma or any of its related parties and the Company did not assume any contingent liabilities or guarantees. For further information concerning the definitive amalgamation agreement entered into with Exxel Pharma, readers are encouraged to review the Company’s news release of June 11, 2018.

At this time, management of the Company anticipates initiating a review of potential strategic acquisition opportunities for the Company and will provide further information on this review as it progresses.

The Company has requested that trading in its common shares resume on the TSX Venture Exchange, and will issue a further news release once the effective date for the resumption has been confirmed.

5.2 Disclosure for Restructuring Transactions

N/A

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7 Omitted Information

None

Item 8 Officer

Sean Davis, President, 604-628-5616

Item 9 Date of Report

March 20, 2019